Cardevaâ„¢ is CoGenesys, Inc.'s long-acting form of b-type natriuretic peptide (BNP) which last week has been granted USFDA approval to commence clinical trial in the United States.

Cardevaâ„¢ (a human serum albumin (HSA)-BNP fusion protein) the most advanced compound in CoGenesys' broad pipeline of improved, long-acting biopharmaceuticals being developed to address unmet medical needs across a broad spectrum of therapeutic areas, have demonstrated in preclinical studies the ability to retain the pharmacological profile of BNP peptide while maintaining a greatly extended half-life and long duration of action.

"BNP stimulates cyclic GMP, which is not only a vasodilator but an inhibitor of the progressive heart muscle structural remodeling that leads to progression of heart failure," according to Jay N. Cohn, M.D., Professor of Medicine at the University of Minnesota.

"Chronic administration of a long- acting BNP could have remarkably favorable effects that must be documented in clinical trials," he said.

Cardevaâ„¢ holds great promise in the treatment of chronic heart failure (CHF) and CoGenesys, Inc. can't wait to get on with the clinical trials and have this available to CHF patients in due time.

Read more at CoGenesys, Inc. (a pdf file)